Glipizide
Sulfonylureas
- Drug class
- Sulfonylureas
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 21
- FDA reports (12 mo)
- 1,539
Overview
Glipizide is an active pharmaceutical ingredient in the Sulfonylureas group (A10BB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 20 | May 7, 2026 |
| GB United Kingdom | MHRA | 1 | August 23, 2024 |
USUnited States· FDA
20 products
Uses
INDICATIONS AND USAGE
Glipizide Tablets USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
How to take
GBUnited Kingdom· MHRA
1 product
Uses
Glipizide is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus.
How to take
Drug interactions
Known interactions involving Glipizide. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 561. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 00729e82-150a-46… · revised March 19, 2026 [PDF]
- [2]MHRA (UK) · PL000571016 · revised August 23, 2024
- [3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.